Lorenzo Rossi

Dr. Lorenzo Rossi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2019 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
LRLorenzo Rossi
Lorenzo Rossi
CMCalogero Mazzara
Calogero Mazzara
OPOlivia Pagani
Olivia Pagani

31 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DSDavide Sparasci
Davide Sparasci
INIlenia Napoli
Ilenia Napoli
LRLorenzo Rossi
Lorenzo Rossi
RPRicardo Pereira-Mestre
Ricardo Pereira-Mestre
MMMauro Manconi
Mauro Manconi
UVUrsula Vogl
Ursula Vogl
Prostate cancer (PCa) treatment involves multiple strategies depending on the disease’s stage. Androgen deprivation therapy (ADT) remains the gold standard for advanced and metastatic stages. Sleep quality has been suggested as being additionally influenced also by local radiotherapy, prostatectomy and androgen-receptor (AR)-targeted agents. We performed a systematic review exploring the landscape of studies published between 1 January 1990 and 31 July 2021, investigating sleep disturbances in PCa patients receiving active treatments, including the influence of hormonal therapy on sleep quality as a factor affecting their quality of life. Out of 45 articles identified, 16 studies were selected, which recruited patients with PCa, undergoing active treatment in either a prospective longitudinal or cross-sectional study. Development of sleep disorders or changes in sleep quality were reported in 14 out of 16 trials included. Only five trials included objective measurements such as actigraphy, mostly at one time point and without a baseline assessment. Limitations to be addressed are the small number of existing trials, lack of randomized trials and heterogeneity of methodologies used. This systematic review outlines the lack of prospective trials investigating sleep disorders, with a rigorous methodology, in homogeneous cohorts of PCa patients. Future trials are needed to clarify the prevalence and impact of this side effect of PCa treatments.

1 March 2019 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
LRLorenzo Rossi
Lorenzo Rossi
AMAmelia McCartney
Amelia McCartney
ISIrene De Santo
Irene De Santo
EREmanuela Risi
Emanuela Risi
EMErica Moretti
Erica Moretti
ALAngelo Di Leo
Angelo Di Leo

29 May 2019 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
LRLorenzo Rossi
Lorenzo Rossi
CBchiara biagioni
chiara biagioni
AMAmelia McCartney
Amelia McCartney
IMIlenia Migliaccio
Ilenia Migliaccio
GCGiuseppe Curigliano
Giuseppe Curigliano
Luca MalorniLuca Malorni
Luca Malorni
Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.

1 April 2020 in Chinese Clinical Oncology
Verified
Journal Article
Open access
PDF file
LRLorenzo Rossi
Lorenzo Rossi
CLClaudio Longhitano
Claudio Longhitano
FKFlorenc Kola
Florenc Kola
MGMaria Del Grande
Maria Del Grande
State of art and advances on the treatment of bone metastases from breast cancer: a concise review Authors: Lorenzo Rossi, Claudio Longhitano, Florenc Kola, Maria Del Grande

29 August 2019 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
AMAmelia McCartney
Amelia McCartney
Alessia VignoliAlessia Vignoli
Alessia Vignoli
Leonardo TenoriLeonardo Tenori
Leonardo Tenori
MFMonica Fornier
Monica Fornier
LRLorenzo Rossi
Lorenzo Rossi
ALAngelo Di Leo
Angelo Di Leo
Despite recent refinements to the 21-gene g score, allowing a better identification of patients who may derive no benefit from the addition of adjuvant chemotherapy to that of endocrine therapy, patients with early breast cancer still stand to be over-treated in the setting of clinical and/or genomic uncertainty or discordance. Here we describe and demonstrate a potential approach of further refining the OncotypeDX risk score by metabolomic analysis of serum. In a clinical dataset (N = 87), the risk of recurrence was further sub-stratified by metabolomic signature, with an effective splitting of each Oncotype risk classification. A total of seven recurrences were recorded, with metabolomic analysis accurately predicting six of these. Contrastingly, the genomic risk score of the seven recurrences ranged across all three Oncotype classifications (one recurrence occurred in the “low”-risk group, three in the “intermediate” group and three in the “high”-risk group).